diazoxide has been researched along with Cardiac Failure in 24 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiotensin II (Ang II) and tumour necrosis factor alpha (TNFalpha) are involved in the progression from compensated hypertrophy to heart failure." | 7.75 | Angiotensin II and tumour necrosis factor alpha as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure. ( Baertschi, AJ; Isidoro Tavares, N; Lerch, R; Montessuit, C; Philip-Couderc, P, 2009) |
| "Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced into clinical practice in the 1950s for the treatment of hypertension." | 5.43 | Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. ( Inoue, Y; Komatsu, Y; Miyoshi, H; Nakamura, A; Tajima, K; Takano, T; Takihata, M; Terauchi, Y; Tsuchiya, H; Yahagi, S; Yamakawa, T; Yoshida, M, 2016) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 5.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| "Cardiorespiratory failure (toxicity) occurred on eight of the 11 occasions (73%) in seven infants." | 5.28 | Complications of diazoxide treatment in persistent neonatal hyperinsulinism. ( Abu-Osba, YK; Manasra, KB; Mathew, PM, 1989) |
| "Diazoxide was administered intravenously in successive 300 mg infusions, each over 10 minutes, until a satisfactory response in cardiac and output occurred or a fall in arterial blood pressure or increase in heart rate was noted." | 5.26 | Beneficial hemodynamic effects of intravenous diazoxide in refractory congestive heart failure. ( Hanlon, JT; Haughom, F; Massie, BM; Stern, R, 1982) |
| "Angiotensin II (Ang II) and tumour necrosis factor alpha (TNFalpha) are involved in the progression from compensated hypertrophy to heart failure." | 3.75 | Angiotensin II and tumour necrosis factor alpha as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure. ( Baertschi, AJ; Isidoro Tavares, N; Lerch, R; Montessuit, C; Philip-Couderc, P, 2009) |
| "Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced into clinical practice in the 1950s for the treatment of hypertension." | 1.43 | Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. ( Inoue, Y; Komatsu, Y; Miyoshi, H; Nakamura, A; Tajima, K; Takano, T; Takihata, M; Terauchi, Y; Tsuchiya, H; Yahagi, S; Yamakawa, T; Yoshida, M, 2016) |
| "Diazoxide is an effective and usually safe medication to treat this type and other types of neonatal HI." | 1.42 | Liver injury may increase the risk of diazoxide toxicity: a case report. ( Garibaldi, L; Mahmood, B; Sperling, M; Tas, E, 2015) |
| "Glibenclamide (10 μM) terminated these arrhythmias and restored APDs to control values." | 1.37 | Effects of KATP channel openers diazoxide and pinacidil in coronary-perfused atria and ventricles from failing and non-failing human hearts. ( Ambrosi, CM; Chang, R; Efimov, IR; Fedorov, VV; Glukhov, AV; Janks, D; Kostecki, G; Moazami, N; Nichols, CG; Schuessler, RB, 2011) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 1.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 1.32 | A case of severe diazoxide toxicity. ( Camporesi, A; Mandelli, A; Salvo, I; Silvani, P; Wolfler, A, 2004) |
| "Cardiorespiratory failure (toxicity) occurred on eight of the 11 occasions (73%) in seven infants." | 1.28 | Complications of diazoxide treatment in persistent neonatal hyperinsulinism. ( Abu-Osba, YK; Manasra, KB; Mathew, PM, 1989) |
| "They suffered serious side effects of cardiac failure and truncal ataxia." | 1.27 | Complications of diazoxide in the treatment of nesidioblastosis. ( McGraw, ME; Price, DA, 1985) |
| "Diazoxide was administered intravenously in successive 300 mg infusions, each over 10 minutes, until a satisfactory response in cardiac and output occurred or a fall in arterial blood pressure or increase in heart rate was noted." | 1.26 | Beneficial hemodynamic effects of intravenous diazoxide in refractory congestive heart failure. ( Hanlon, JT; Haughom, F; Massie, BM; Stern, R, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (70.83) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brennan, S | 1 |
| Jackson, R | 1 |
| Patel, M | 1 |
| Sims, MW | 1 |
| Hudman, D | 1 |
| Norman, RI | 1 |
| Lodwick, D | 1 |
| Rainbow, RD | 1 |
| Tas, E | 1 |
| Mahmood, B | 1 |
| Garibaldi, L | 1 |
| Sperling, M | 1 |
| Komatsu, Y | 1 |
| Nakamura, A | 1 |
| Takihata, M | 1 |
| Inoue, Y | 1 |
| Yahagi, S | 1 |
| Tajima, K | 1 |
| Tsuchiya, H | 1 |
| Takano, T | 1 |
| Yamakawa, T | 1 |
| Yoshida, M | 1 |
| Miyoshi, H | 1 |
| Terauchi, Y | 1 |
| Yildizdas, D | 1 |
| Erdem, S | 1 |
| Küçükosmanoglu, O | 1 |
| Yilmaz, M | 1 |
| Yüksel, B | 1 |
| Isidoro Tavares, N | 1 |
| Philip-Couderc, P | 1 |
| Baertschi, AJ | 1 |
| Lerch, R | 1 |
| Montessuit, C | 1 |
| Fedorov, VV | 1 |
| Glukhov, AV | 1 |
| Ambrosi, CM | 1 |
| Kostecki, G | 1 |
| Chang, R | 1 |
| Janks, D | 1 |
| Schuessler, RB | 1 |
| Moazami, N | 1 |
| Nichols, CG | 1 |
| Efimov, IR | 1 |
| Silvani, P | 1 |
| Camporesi, A | 1 |
| Mandelli, A | 1 |
| Wolfler, A | 1 |
| Salvo, I | 1 |
| Finnerty, FA | 5 |
| Davidov, M | 3 |
| Kakaviatos, N | 2 |
| Fischer, E | 1 |
| Siegenthaler, W | 1 |
| Brandt, D | 2 |
| Massie, BM | 1 |
| Stern, R | 1 |
| Hanlon, JT | 1 |
| Haughom, F | 1 |
| Sterz, H | 1 |
| Romankiewicz, JA | 1 |
| Kossmann, CE | 1 |
| Abu-Osba, YK | 1 |
| Manasra, KB | 1 |
| Mathew, PM | 1 |
| McGraw, ME | 1 |
| Price, DA | 1 |
| Gillies, DR | 1 |
| Fernandes, M | 1 |
| Kim, KE | 1 |
| Moyer, JH | 1 |
| Mauer, SM | 1 |
| Mirkin, BL | 1 |
| Mroczek, WJ | 1 |
| Gavrilovich, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation[NCT00994149] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2009-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for diazoxide and Cardiac Failure
| Article | Year |
|---|---|
[Therapy of hypertensive crisis].
Topics: Acute Disease; Bed Rest; Cardiac Glycosides; Clonidine; Diazoxide; Dihydralazine; Diuretics; Heart F | 1980 |
[New aspects in the treatment of acute cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Droperidol; Fent | 1978 |
Pharmacology and clinical use of drugs in hypertensive emergencies.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Aorta; Brain Diseases; Cerebral Hemorrhage; Diazox | 1977 |
Hypertensive emergencies.
Topics: Acute Kidney Injury; Adrenal Gland Neoplasms; Antihypertensive Agents; Aortic Aneurysm; Blood Volume | 1974 |
20 other studies available for diazoxide and Cardiac Failure
| Article | Year |
|---|---|
Early opening of sarcolemmal ATP-sensitive potassium channels is not a key step in PKC-mediated cardioprotection.
Topics: Action Potentials; Adenosine; Animals; Cardiotonic Agents; Cell Separation; Diazoxide; Enzyme Activa | 2015 |
Liver injury may increase the risk of diazoxide toxicity: a case report.
Topics: Albumins; Blood Glucose; Chemical and Drug Induced Liver Injury; Diazoxide; Heart Failure; Humans; H | 2015 |
Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diazoxide; Drug Monitoring; Drug Resistance; Edema | 2016 |
Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy.
Topics: Congenital Hyperinsulinism; Diazoxide; Female; Heart Failure; Humans; Hypertension, Pulmonary; Infan | 2008 |
Angiotensin II and tumour necrosis factor alpha as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure.
Topics: Action Potentials; Angiotensin II; Animals; ATP-Binding Cassette Transporters; Cells, Cultured; Diaz | 2009 |
Effects of KATP channel openers diazoxide and pinacidil in coronary-perfused atria and ventricles from failing and non-failing human hearts.
Topics: Action Potentials; Adolescent; Adult; Arrhythmias, Cardiac; Coronary Vessels; Diazoxide; Female; Gen | 2011 |
A case of severe diazoxide toxicity.
Topics: Blood Glucose; Diazoxide; Edema; Heart Failure; Humans; Hyperinsulinism; Infant; Male; Pancreatectom | 2004 |
Hypertensive vascular disease. The long term effect of rapid repeated reductions of arterial pressure with diazoxide.
Topics: Adult; Chlorthalidone; Diazoxide; Female; Heart Failure; Humans; Hydralazine; Hypertension; Injectio | 1967 |
[Vasodilators in heart failure? Basic principles and its role in practice].
Topics: Adrenergic alpha-Antagonists; Captopril; Diazoxide; Furosemide; Heart Failure; Humans; Hydralazine; | 1981 |
[The hypertensive crisis].
Topics: Acute Disease; Calcium Channel Blockers; Clonidine; Coronary Disease; Diazoxide; Dihydralazine; Dilt | 1984 |
Beneficial hemodynamic effects of intravenous diazoxide in refractory congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiac Volume; Diazoxide; Heart Failure; Hemodynamics; | 1982 |
Contraindications to digitalis in congestive "heart" failure.
Topics: Diazoxide; Digitalis Glycosides; Furosemide; Heart Failure; Humans; Hypertension; Male; Methyldopa; | 1977 |
Complications of diazoxide treatment in persistent neonatal hyperinsulinism.
Topics: Blood Glucose; Diazoxide; Female; Heart Failure; Humans; Hyperinsulinism; Hypoglycemia; Infant; Insu | 1989 |
Complications of diazoxide in the treatment of nesidioblastosis.
Topics: Ataxia; Diazoxide; Heart Failure; Humans; Infant; Infant, Newborn; Male; Pancreatic Diseases | 1985 |
Complications of diazoxide in the treatment of nesidioblastosis.
Topics: Diazoxide; Female; Heart Failure; Humans; Infant, Newborn; Pancreatic Diseases | 1985 |
Aggressive drug therapy in accelerated hypertension.
Topics: Antihypertensive Agents; Aortic Aneurysm; Brain Diseases; Cerebrovascular Disorders; Diazoxide; Ferr | 1974 |
Treatment of hypertension in infancy with diazoxide: report of a case with arrhythmia as a complications of therapy.
Topics: Arrhythmias, Cardiac; Blood Pressure; Coronary Disease; Diazoxide; Female; Heart Failure; Humans; Hy | 1972 |
The long term effect of repeated acute reductions of arterial pressure with diazoxide in patients with severe hypertension.
Topics: Acidosis; Blood Glucose; Diazoxide; Heart; Heart Failure; Humans; Hyperaldosteronism; Hypertension; | 1968 |
The value of aggressive therapy in the hypertensive patient with azotemia.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Arteries; Blood Pressure; Blood Urea Nitrogen; | 1969 |
Failure of repeated diazoxide injections to modify the course of severe hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diazoxide; Diuretics; Guanethidine; Heart F | 1971 |